An open label, dose escalation followed by dose expansion, safety and tolerability trial of CAN04, a fully humanized monoclonal antibody against IL1RAP, in subjects with solid malignant tumors

Cancer type: Breast cancer, Colorectal cancer, Lung cancer, Multiple diagnosis, Pancreatic cancer, Solide tumores

Phase: I/II

Principal Investigator: Guren Tormod

Country: NO

Keywords: Norway, Oslo, CANFOUR, IL1RAP, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Ductal Adenocarcinoma (PDAC), Triple negative Breast Cancer (TNBC), Colorectal Cancer (CRC)

Status: Inclusion completed

Link to